NRGene and Tel Aviv Sourasky Medical Center Collaborate on Parkinson's Genomes; Tel Aviv Sourasky Medical Center and NRGene research exploring protection again neurodegenerative disease

M2 PressWIRE |

Tel Aviv & Ness Ziona, Israel - - NRGene, the worldwide leader in genomic assembly and analysis, has partnered with the Genetic Institute of Tel Aviv Sourasky Medical Center (TASMC) to perform genomic analysis of Parkinson's disease (PD).

"Our collaboration with NRGene and use of its advanced technology allows us to do comprehensive genetic research on Parkinson's," said Professor Avi Orr-Urtreger, director of TASMC Genetic Institute. "The GenoMAGICTM system will allow us to characterize the genetics of the cohort completely and efficiently."

TASMC is leading successful combined clinical and genetics research aiming for better understanding, treatment, and prevention of Parkinson's disease. This 12-year-old collaboration between the department of Neurology (Prof. Nir Giladi) and the Genetic Institute has already yielded international collaboration and support, as well as dozens of scientific publications. Currently, the study cohort in TASMC includes thousands of individuals and a wealth of data.

NRGene's GenoMAGICTM, a cutting-edge cloud-based genomic analytic system, will efficiently analyze the genomic data of a Parkinson's patients cohort and identify individuals' unique genomic makeup. Correlating genomic differences with disease phenotypes could reveal novel PD-related genes and the interaction between multiple genetic and environmental risk factors.

"NRGene has already proven its ability to analyze large scale genomic datasets and accurately identify key genes and mutations affecting individuals," said NRGene CEO Gil Ronen. "We are proud that our unique genomic tools are supporting genetic studies of Parkinson's disease. The identification of genes involved in the development of the disease will improve our understanding of it and will potentially lead to new drug targets and treatment strategies."

About NRGene

NRGene is a genomic big data company developing cutting-edge software and algorithms to reveal the complexity and diversity of humans, plants and animals for supporting the most advanced medical research and sophisticated breeding programs. NRGene tools have already been employed by some of the leading seed companies worldwide as well as the most influential research teams in academia.

NRGene Contact

Amy Kenigsberg

K2 Global Communications

+1-913-440-4072 (+7 ET)

+972-9-794-1681 (+2 GMT)

TASMC contact

Miki Roll PhD, MBA

Deputy Director General for R&D

Tel: 972-3-6974761

Fax: 972-3-6925739


DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Millennium Blockchain Inc

THC Therapeutics Inc is a health and healing company in the cannabis industry. The Company is engaged in developing dHydronator which is used to reduce moisture and effectively dry out…

Private Markets

The Green Organic Dutchman

The Green Organic Dutchman Ltd. ("TGOD") produces farm grown, organic cannabis for medical use. The company grows its high quality organic cannabis in small batches using craft growing, all natural…


Voleo is a free download that allows you to form investment clubs with your friends, family, colleagues, classmates, teammates…basically anyone you know and trust. Invest and manage a stock portfolio…